second generation cll treatment: zanubrutinib sonrotoclax | constantine tam, md, mbbs | ash 2023
Published 10 months ago • 754 plays • Length 2:37Download video MP4
Download video MP3
Similar videos
-
2:00
alpine trial: zanubrutinib vs ibrutinib in treating #cll | constantine tam, md, mbbs | ash 2023
-
2:36
sonrotoclax plus zanubrutinib combination shows promise in treatment-naïve cll/sll
-
5:23
constantine tam: zanubrutinib active in treatment-naïve cll/sll
-
4:41
zanubrutinib combined with venetoclax for cll patients with deletion 17p - dr. constantine tam
-
3:18
benjamin lampson: acalabrutinib combo leads to deep, durable responses in frontline cll
-
9:10
dr constantine tam: living with chronic lymphocytic leukaemia (cll) part 1 of 4
-
2:07
sequoia: zanubrutinib vs br in treatment-naïve cll/sll
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
13:55
dr constantine tam: living with chronic lymphocytic leukaemia (cll) part 4 of 4
-
2:46
optimizing the combination of ibrutinib plus venetoclax in cll
-
0:50
alternative cellular therapies for patients with cll
-
4:05
bcl2 and btk dual-inhibition with sonrotoclax zanubrutinib in previously untreated cll and sll
-
2:14
ibrutinib's role in cll treatment and future outlooks
-
1:48
zanubrutinib plus obinutuzumab: cll, sll & fl
-
9:49
sonrotoclax plus zanubrutinib shows deep response in cll
-
1:22
combined acalabrutinib treatments for cll
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
1:08
constantine tam, mbbs, md, considers the role of car-t cell therapy in chronic lymphocytic leukemia
-
1:36
evaluating acalabrutinib in cll treatment
-
1:53
change of landscape in cll treatment
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll